“…[1][2][3][4][5][6][7][8][9][10] Most of these reports are small case series or individual case reports. [3][4][5][6][7][8][9][10] In the multicenter, placebo-controlled, phase II study (SPIRIT trial) presented by Gottlieb et al, 2 249 patients with moderate to severe plaque psoriasis were randomized to receive placebo, 3 mg/kg, or 5 mg/kg of infliximab at baseline (week 0), 2, and 6 weeks. No concomitant systemic or topical therapies for psoriasis were allowed.…”